Global sleep apnea diagnostic devices market was valued at USD 4.89 Billion in 2023, growing at a CAGR of 6.92% during the forecast period from 2024 to 2030 to reach USD 7.30 Billion by 2030. The increase in demand for sleep apnea diagnostic devices is primarily attributed to the rising prevalence of sleep apnea diseases worldwide due to unhealthy lifestyles and excess body weight. Moreover, the increasing number of geriatric population and the increasing prevalence of comorbidities such as hypertension, diabetes, obesity, and cardiovascular diseases will propel the market growth of the device in the market. Additionally, the increasing awareness about the symptoms of the sleep apnea across the world are anticipated to bolster the market, thereby contributing to the growth of the sleep apnea diagnostic devices market during the forecast period from 2024-2030.
The rise in prevalence of obesity worldwide due to unhealthy eating and sedentary lifestyle, across the world are anticipated to bolster the market. For instance, according to World Obesity 2022, it is estimated globally that 2.7 billion adults will be overweight in 2025, over 1 billion will be affected by obesity, and 177 million adults will be severely affected with obesity by 2025. In obese people, fat deposits in the upper respiratory tract narrow the airway; there is a decrease in muscle activity in this region, leading to hypoxic and apneic episodes, ultimately resulting in sleep apnea. The increasing incidence of obesity may increase the risk of sleep apnea in the obese person. The increasing incidence of the sleep apnea can be reduced by doing proper diagnosis and by giving proper treatments. The diagnosis of the disorder is done be the diagnostic devices. Thus, the rising number of obese people may increase the incidence of the sleep apnea ultimately increasing the demand of the sleep apnea diagnostic devices thereby anticipated to propel the overall market growth of the device in the forecast period of 2022 - 2028.
Moreover, the increasing prevalence of chronic obstructive pulmonary disease (COPD) will also propel the demand of the sleep apnea diagnostic devices. For instance, according to the data published by World Health Organization (WHO) 2022, it was estimated that COPD was the third leading cause of death worldwide, causing 3.23 million deaths in the year 2019. Additionally, nearly 90% of COPD deaths were those in patients under 70 years of age in low- and middle-income countries. Moreover, COPD causes persistent and progressive respiratory symptoms, including difficulty in breathing, cough and phlegm production. The disorder results from long-term exposure to harmful gases and particles combined with individual factors, including events which influence lung growth in childhood and genetics. Early diagnosis and treatment, including smoking cessation support is required to slow down the incidence and mortality rate from the disease. People with COPD also have sleep apnea. The combination is called "overlap syndrome" and it raises the chances of having hypercapnia (too much carbon dioxide in your blood) and pulmonary hypertension (high blood pressure in the lungs' arteries). The increasing prevalence of COPD may increase the prevalence of sleep apnea. To detect the presence of the sleep apnea diagnostic devices are used, increasing the demand of the device in the market. Henceforth, the increasing prevalence of COPD will increase the prevalence of sleep apnea, ultimately increasing the demand of the device, thereby leading to bolster the overall market growth of the sleep apnea diagnostic devices in the forecast period of 2022 - 2028.
However, high costs of the device and the restricted reimbursement for the devices may hamper the sleep apnea diagnostic devices market growth.
The ongoing COVID-19 pandemic has negatively impacted the market for sleep apnea diagnostic devices as patients postponed hospital exposure and elective surgeries. Hospital admissions for patients suffering from chronic disorders were not a priority in comparison to the patients suffering from coronavirus. Due to stringent lockdown rules production of some medical devices was shut down. Therefore, there was a decline in sleep apnea diagnostic devices market. However, with normalcy and with masses being vaccine, the market is picking up the momentum again as the number of surgeries are increasing again. Additionally, it is believed that the pandemic has increased the sedentary lifestyle, prevalence of obesity and overweight globally. This may lead to the increase in the demand of sleep apnea diagnostic devices in the forecast period of 2022 - 2028.
In the product type segment of the sleep apnea diagnostic devices market, the polysomnography is estimated to hold a significant share in the sleep apnea diagnostic devices market in the year 2023. This can be ascribed to the various advantages that are associated with the segment.
Polysomnography is the simultaneous recording of multiple physiologic signals during sleep. The signals generally included are brain waves, eye movements, chin muscle activity, air flow from the nose and mouth, chest and abdominal movement, blood oxygen levels, heart rate and rhythm, and leg movements. This is usually done in the presence of a technician so the patients feel comfortable during the procedure.
Additionally, polysomnography measures many movements related to the sleep. With this test, smaller number of physiologic signals are recorded.
Moreover, the product launches, in turn, drive the product demand in the market. For instance, in April 2022, Onera Health, a leader in transforming sleep medicine and remote monitoring, announced that Onera B.V., has received 510(k) market clearance from the U.S. Food & Drug Administration (FDA) for its ground-breaking system for Polysomnography (PSG) studies, Onera STS, paving the way for widespread deployment of the patch-based technology across healthcare systems in the U.S.
Thus, owing to the various advantages and an increase in the launch and approvals of polysomnography, there will be an increase in the demand for polysomnography, which in turn will drive the sleep apnea diagnostic devices market growth.
Rising prevalence of sleep apnea diseases in the region due to unhealthy lifestyles and excess body weight and the increasing prevalence of comorbidities such as hypertension, diabetes, obesity, and cardiovascular diseases in the North America will increase the demand of the devices, leading to a rise in the overall sleep apnea diagnostic devices market growth. Moreover, the increasing awareness about the symptoms of the sleep apnea across the North America are anticipated to bolster the market.
According to Centers for Disease Control and Prevention (CDC) 2022, it was estimated that in the year 2020 the prevalence of obesity in the United States increased from 4.7% to 9.2%. Moreover as per the same source, the obesity prevalence in US was 39.8% among adults aged 20 to 39 years, 44.3% among adults aged 40 to 59 years, and 41.5% among adults aged 60 and older in the year 2020. Additionally, as per World Obesity Atlas 2022, it is estimated that in the Americas region, one in three men (34.41%) and almost two-fifths of women (39.72%) are predicted to have a BMI ≥30kg/m2 by 2030. This accounts for approximately 134 million men and 164 million women in the North America, at risk of the complications of obesity by 2030. Of these, over 49 million men are predicted to have a BMI of ≥35kg/m2 and almost 17 million are predicted to have a BMI of ≥40kg/m2, while 79 million women are predicted to have a BMI of ≥35kg/m2 and over 32 million a BMI of ≥40 kg/m2. People with BMI of ≥25kg/m2 are considered overweight and with BMI of ≥30 kg/m2 are considered obese. The increasing incidence of obesity and overweight may increase the risk of developing sleep apnea. The sleep apnea can be diagnosed and treated properly to reduce the prevalence of the disorder in the region, leading to the increased demand of the sleep apnea diagnostic devices, thereby bolster the overall market growth of the devices in the North America in the year 2023 - 2028.
Furthermore, the increasing prevalence of chronic disorders such as hypertension, diabetes, and other may increase the risk of developing of the sleep apnea. For instance, as per the data published by the Centers of Disease Prevention and Control (CDC) 2022, it was estimated that in the year 2019, nearly half of adults in the United States (47%, or 116 million) had hypertension. Moreover, the patients with high blood pressure have sleep apnea. However, sleep apnea is much more common in patients with resistant hypertension, who have tried a variety of high blood pressure treatments but can’t get their condition under control. Thus, the increasing prevalence of the hypertension may increase the risk of developing sleep apnea. Sleep apnea can only be treated when its diagnosis is done properly. The diagnosis of the sleep apnea can be done by devices such as oximeter, polysomnography device [PSG], sleep apnea screening device, actigraphy monitoring device, and other devices. Therefore, increasing the demand of the devices in the market, thereby the above factor is anticipated to bolster the overall market growth of the sleep apnea devices in the forecast period of 2022 - 2028.
Thus, all the above-mentioned factors are anticipated to propel the market for sleep apnea diagnostic devices in the North America.
This product will be delivered within 2 business days.
Sleep Apnea Diagnostic Devices Market Dynamics:
The sleep apnea diagnostic devices market is witnessing a growth in product demand owing to various reasons.The rise in prevalence of obesity worldwide due to unhealthy eating and sedentary lifestyle, across the world are anticipated to bolster the market. For instance, according to World Obesity 2022, it is estimated globally that 2.7 billion adults will be overweight in 2025, over 1 billion will be affected by obesity, and 177 million adults will be severely affected with obesity by 2025. In obese people, fat deposits in the upper respiratory tract narrow the airway; there is a decrease in muscle activity in this region, leading to hypoxic and apneic episodes, ultimately resulting in sleep apnea. The increasing incidence of obesity may increase the risk of sleep apnea in the obese person. The increasing incidence of the sleep apnea can be reduced by doing proper diagnosis and by giving proper treatments. The diagnosis of the disorder is done be the diagnostic devices. Thus, the rising number of obese people may increase the incidence of the sleep apnea ultimately increasing the demand of the sleep apnea diagnostic devices thereby anticipated to propel the overall market growth of the device in the forecast period of 2022 - 2028.
Moreover, the increasing prevalence of chronic obstructive pulmonary disease (COPD) will also propel the demand of the sleep apnea diagnostic devices. For instance, according to the data published by World Health Organization (WHO) 2022, it was estimated that COPD was the third leading cause of death worldwide, causing 3.23 million deaths in the year 2019. Additionally, nearly 90% of COPD deaths were those in patients under 70 years of age in low- and middle-income countries. Moreover, COPD causes persistent and progressive respiratory symptoms, including difficulty in breathing, cough and phlegm production. The disorder results from long-term exposure to harmful gases and particles combined with individual factors, including events which influence lung growth in childhood and genetics. Early diagnosis and treatment, including smoking cessation support is required to slow down the incidence and mortality rate from the disease. People with COPD also have sleep apnea. The combination is called "overlap syndrome" and it raises the chances of having hypercapnia (too much carbon dioxide in your blood) and pulmonary hypertension (high blood pressure in the lungs' arteries). The increasing prevalence of COPD may increase the prevalence of sleep apnea. To detect the presence of the sleep apnea diagnostic devices are used, increasing the demand of the device in the market. Henceforth, the increasing prevalence of COPD will increase the prevalence of sleep apnea, ultimately increasing the demand of the device, thereby leading to bolster the overall market growth of the sleep apnea diagnostic devices in the forecast period of 2022 - 2028.
However, high costs of the device and the restricted reimbursement for the devices may hamper the sleep apnea diagnostic devices market growth.
The ongoing COVID-19 pandemic has negatively impacted the market for sleep apnea diagnostic devices as patients postponed hospital exposure and elective surgeries. Hospital admissions for patients suffering from chronic disorders were not a priority in comparison to the patients suffering from coronavirus. Due to stringent lockdown rules production of some medical devices was shut down. Therefore, there was a decline in sleep apnea diagnostic devices market. However, with normalcy and with masses being vaccine, the market is picking up the momentum again as the number of surgeries are increasing again. Additionally, it is believed that the pandemic has increased the sedentary lifestyle, prevalence of obesity and overweight globally. This may lead to the increase in the demand of sleep apnea diagnostic devices in the forecast period of 2022 - 2028.
Sleep Apnea Diagnostic Devices Market Segment Analysis:
Sleep Apnea Diagnostic Devices Market by Product Type (Polysomnography Device [PSG], Sleep Apnea Screening Device, Actigraphy Monitoring Device, Respiratory Polygraph, and Oximeter), by End User (Hospitals & Clinics, Homecare Setting, and Sleep Laboratories), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World)In the product type segment of the sleep apnea diagnostic devices market, the polysomnography is estimated to hold a significant share in the sleep apnea diagnostic devices market in the year 2023. This can be ascribed to the various advantages that are associated with the segment.
Polysomnography is the simultaneous recording of multiple physiologic signals during sleep. The signals generally included are brain waves, eye movements, chin muscle activity, air flow from the nose and mouth, chest and abdominal movement, blood oxygen levels, heart rate and rhythm, and leg movements. This is usually done in the presence of a technician so the patients feel comfortable during the procedure.
Additionally, polysomnography measures many movements related to the sleep. With this test, smaller number of physiologic signals are recorded.
Moreover, the product launches, in turn, drive the product demand in the market. For instance, in April 2022, Onera Health, a leader in transforming sleep medicine and remote monitoring, announced that Onera B.V., has received 510(k) market clearance from the U.S. Food & Drug Administration (FDA) for its ground-breaking system for Polysomnography (PSG) studies, Onera STS, paving the way for widespread deployment of the patch-based technology across healthcare systems in the U.S.
Thus, owing to the various advantages and an increase in the launch and approvals of polysomnography, there will be an increase in the demand for polysomnography, which in turn will drive the sleep apnea diagnostic devices market growth.
North America is expected to dominate the overall Sleep Apnea Diagnostic Devices Market:
Among all the regions, North America is estimated to achieve a significant share in the global sleep apnea diagnostic devices market.Rising prevalence of sleep apnea diseases in the region due to unhealthy lifestyles and excess body weight and the increasing prevalence of comorbidities such as hypertension, diabetes, obesity, and cardiovascular diseases in the North America will increase the demand of the devices, leading to a rise in the overall sleep apnea diagnostic devices market growth. Moreover, the increasing awareness about the symptoms of the sleep apnea across the North America are anticipated to bolster the market.
According to Centers for Disease Control and Prevention (CDC) 2022, it was estimated that in the year 2020 the prevalence of obesity in the United States increased from 4.7% to 9.2%. Moreover as per the same source, the obesity prevalence in US was 39.8% among adults aged 20 to 39 years, 44.3% among adults aged 40 to 59 years, and 41.5% among adults aged 60 and older in the year 2020. Additionally, as per World Obesity Atlas 2022, it is estimated that in the Americas region, one in three men (34.41%) and almost two-fifths of women (39.72%) are predicted to have a BMI ≥30kg/m2 by 2030. This accounts for approximately 134 million men and 164 million women in the North America, at risk of the complications of obesity by 2030. Of these, over 49 million men are predicted to have a BMI of ≥35kg/m2 and almost 17 million are predicted to have a BMI of ≥40kg/m2, while 79 million women are predicted to have a BMI of ≥35kg/m2 and over 32 million a BMI of ≥40 kg/m2. People with BMI of ≥25kg/m2 are considered overweight and with BMI of ≥30 kg/m2 are considered obese. The increasing incidence of obesity and overweight may increase the risk of developing sleep apnea. The sleep apnea can be diagnosed and treated properly to reduce the prevalence of the disorder in the region, leading to the increased demand of the sleep apnea diagnostic devices, thereby bolster the overall market growth of the devices in the North America in the year 2023 - 2028.
Furthermore, the increasing prevalence of chronic disorders such as hypertension, diabetes, and other may increase the risk of developing of the sleep apnea. For instance, as per the data published by the Centers of Disease Prevention and Control (CDC) 2022, it was estimated that in the year 2019, nearly half of adults in the United States (47%, or 116 million) had hypertension. Moreover, the patients with high blood pressure have sleep apnea. However, sleep apnea is much more common in patients with resistant hypertension, who have tried a variety of high blood pressure treatments but can’t get their condition under control. Thus, the increasing prevalence of the hypertension may increase the risk of developing sleep apnea. Sleep apnea can only be treated when its diagnosis is done properly. The diagnosis of the sleep apnea can be done by devices such as oximeter, polysomnography device [PSG], sleep apnea screening device, actigraphy monitoring device, and other devices. Therefore, increasing the demand of the devices in the market, thereby the above factor is anticipated to bolster the overall market growth of the sleep apnea devices in the forecast period of 2022 - 2028.
Thus, all the above-mentioned factors are anticipated to propel the market for sleep apnea diagnostic devices in the North America.
Sleep Apnea Diagnostic Devices Market Key Players:
Some of the key market players operating in the sleep apnea diagnostic devices market include Natus Medical Incorporated., SOMNOmedicsGmbH, Compumedics Limited, ZOLL Itamar Ltd., Nihon Kohden Corporation, Vyaire., Cleveland Medical Devices Inc., Cadwell Industries Inc., Koninklijke Philips N.V., InMode Aesthetic Solutions, ResMed, Resonea, DeVilbiss Healthcare LLC, Smiths Group Plc. (Smiths Medical), Hemodiaz Life Sciences Private Limited., ActiGraph, LLC., Advin Health Care, Recorders & Medicare Systems Pvt Ltd (RMS), Allengers, EB Neuro S.p.A., among others.Recent Developmental Activities in the Sleep Apnea Diagnostic Devices Market:
- In November 2022, Acurable, UK medical device firm has earned FDA 510(k) clearance for its AcuPebble SA100 home sleep apnea testing device. The small, wearable device provides automated, remote home testing for obstructive sleep apnea (OSA).
- In September 2022, Asahi Kasei unit ZOLL Medical has entered a definitive agreement to acquire medical device and digital health company Itamar Medical for nearly $538m.
- In June 2022, Somnoware one of the leading player of digital sleep and respiratory health management announced its collaboration with Itamar Medical, another leading Israeli sleep apnea company. The company announced the integration of the WatchPAT One device with its Sleep Device Interface (SDI) that provides manufacturer independent, browser-based interface of diagnostic device operations.
Key Takeaways from the Sleep Apnea Diagnostic Devices Market Report Study
- Market size analysis for current sleep apnea diagnostic devices market size (2023), and market forecast for 6 years (2024-2030)
- The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the sleep apnea diagnostic devices market.
- Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
- Key companies dominating the global sleep apnea diagnostic devices market.
- Various opportunities available for the other competitor in the sleep apnea diagnostic devices market space.
- What are the top performing segments in 2023? How these segments will perform in 2030.
- Which is the top-performing regions and countries in the current sleep apnea diagnostic devices market scenario?
- Which are the regions and countries where companies should have concentrated on opportunities for sleep apnea diagnostic devices market growth in the coming future?
Target Audience who can be benefited from this Sleep Apnea Diagnostic Devices Market Report Study
- Sleep apnea diagnostic devices products providers
- Research organizations and consulting companies
- Sleep apnea diagnostic devices-related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and Traders dealing in sleep apnea diagnostic devices
- Various End-users who want to know more about the sleep apnea diagnostic devices market and latest technological developments in the sleep apnea diagnostic devices market.
Frequently Asked Questions for Sleep Apnea Diagnostic Devices Market:
1. What are Sleep apnea diagnostic devices?
A sleep apnea diagnostic devices, are the medical devices used to diagnose the presence of sleep apnea in a patient. These devices monitor the brain signals movements or monitor respiration of a patient.2. What is the market for Global Sleep apnea diagnostic devices?
Global sleep apnea diagnostic devices market was valued at USD 4.89 Billion in 2023, growing at a CAGR of 6.92% during the forecast period from 2024 to 2030 to reach USD 7.30 Billion by 2030.3. What are the drivers for the Global Sleep apnea diagnostic devices Market?
The sleep apnea diagnostic devices market is witnessing a positive market growth owing to the rising prevalence of sleep apnea diseases worldwide due to unhealthy lifestyles and excess body weight. Moreover, the increasing number of geriatric population and the increasing prevalence of comorbidities such as hypertension, diabetes, obesity, and cardiovascular diseases will propel the market growth of the device in the market. Additionally, the increasing awareness about the symptoms of the sleep apnea across the world are anticipated to bolster the market.4. Who are the key players operating in the global sleep apnea diagnostic devices market?
Some of the key market players operating in the sleep apnea diagnostic devices market include Natus Medical Incorporated., SOMNOmedicsGmbH, Compumedics Limited, ZOLL Itamar Ltd., Nihon Kohden Corporation, Vyaire., Cleveland Medical Devices Inc., Cadwell Industries Inc., Koninklijke Philips N.V., InMode Aesthetic Solutions, ResMed, Resonea, DeVilbiss Healthcare LLC, Smiths Group Plc. (Smiths Medical), Hemodiaz Life Sciences Private Limited., ActiGraph, LLC., Advin Health Care, Recorders & Medicare Systems Pvt Ltd (RMS), Allengers, EB Neuro S.p.A., and others.5. Which region has the highest share in Sleep apnea diagnostic devices Market?
North America is expected to hold the highest share in the revenue in the sleep apnea diagnostic devices market during the forecast period. Rising prevalence of sleep apnea diseases worldwide due to unhealthy lifestyles and excess body weight and the increasing prevalence of comorbidities such as hypertension, diabetes, obesity, and cardiovascular diseases will increase the demand for sleep apnea diagnostic devices in North America, leading to a rise in the overall sleep apnea diagnostic devices market growth in this region.This product will be delivered within 2 business days.
Table of Contents
1. Sleep Apnea Diagnostic Devices Market Report Introduction6. COVID-19 Impact Analysis on Sleep Apnea Diagnostic Devices Market8. Sleep Apnea Diagnostic Devices Market Global Company Share Analysis - Key 3-5 Companies10. KOL Views11. Project Approach12. About the Publisher13. Disclaimer
2. Sleep Apnea Diagnostic Devices Market Executive Summary
3. Regulatory Analysis
4. Sleep Apnea Diagnostic Devices Market Key Factors Analysis
5. Sleep Apnea Diagnostic Devices Market Porter’s Five Forces Analysis
7. Sleep Apnea Diagnostic Devices Market Layout
9. Sleep Apnea Diagnostic Devices Market Company and Product Profiles
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Natus Medical Incorporated.
- SOMNOmedicsGmbH
- Compumedics Limited
- ZOLL Itamar Ltd
- Nihon Kohden Corporation
- Vyaire
- Cleveland Medical Devices Inc
- Cadwell Industries Inc.
- Koninklijke Philips N.V.
- InMode Aesthetic Solutions
- ResMed
- Resonea
- DeVilbiss Healthcare LLC
- Smiths Group Plc. (Smiths Medical)
- Hemodiaz Life Sciences Private Limited.
- ActiGraph, LLC.
- Advin Health Care
- Recorders & Medicare Systems Pvt Ltd (RMS
- Allengers
- EB Neuro S.p.A